

Supplementary Table 3. Baseline characteristics of the study population (2015 to 2019)

Characteristic	T2DM (all) ^a	T2DM+ASCVD ^b	T2DM+HF ^b
Number	4,736,493	1,720,996	783,378
Age, yr	61.8 ± 13.1	67.7 ± 11.6	69.7 ± 12.1
Male sex	2,642,345 (55.8)	929,289 (54.0)	405,055 (51.7)
Urban residents	2,063,227 (43.6)	727,665 (42.3)	317,272 (40.5)
Income (lowest 25%)	1,226,679 (25.9)	480,604 (27.9)	232,938 (29.7)
Incomes			
Basic livelihood security recipient	362,946 (7.7)	183,463 (10.7)	98,719 (12.6)
Quartile 1	863,733 (18.2)	297,141 (17.3)	134,219 (17.1)
Quartile 2	838,631 (17.7)	267,983 (15.6)	118,189 (15.1)
Quartile 3	1,090,330 (23.0)	365,474 (21.2)	161,358 (20.6)
Quartile 4 (highest)	1,580,853 (33.4)	606,935 (35.3)	270,893 (34.6)
Anti-diabetic drugs			
Metformin (yes)	4,033,190 (85.2)	1,392,190 (80.9)	582,777 (74.4)
DPP-4i (yes)	2,364,640 (49.9)	958,080 (55.7)	459,059 (58.6)
Sulfonylureas (yes)	1,915,899 (40.5)	770,741 (44.8)	344,289 (44.0)
Insulin (yes)	877,195 (18.5)	525,222 (30.5)	346,238 (44.2)
TZD (yes)	392,026 (8.3)	170,162 (9.9)	78,297 (10.0)
AGI (yes)	171,902 (3.6)	73,157 (4.3)	30,082 (3.8)
Meglitinides (yes)	39,899 (0.8)	21,493 (1.3)	11,576 (1.5)
SGLT2i (yes)	198,566 (4.2)	89,472 (5.2)	47,258 (6.0)
GLP-1RA (yes)	4,491 (0.1)	5,484 (0.3)	3,747 (0.5)
CV medications			
ACEi/ARB (yes)	2,372,207 (50.1)	1,092,182 (63.5)	529,111 (67.5)
Statins (yes)	2,717,847 (57.4)	1,247,226 (72.5)	551,554 (70.4)
ASA (yes)	1,315,742 (27.8)	910,874 (52.9)	401,663 (51.3)
Beta-blockers (yes)	560,010 (11.8)	407,463 (23.7)	260,705 (33.3)
Comorbidities			
Hypertension (yes)	2,921,189 (61.7)	1,356,887 (78.8)	669,186 (85.4)
Dyslipidemia (yes)	2,851,332 (60.2)	1,267,993 (73.7)	559,063 (71.4)

Values are presented as mean ± standard deviation or number (%).

T2DM, type 2 diabetes mellitus; ASCVD, atherosclerotic cardiovascular disease; HF, heart failure; DPP-4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1RA, glucagon-like peptide 1 receptor agonist; CV, cardiovascular; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, aspirin.

^aData base on the year in which the International Classification of Disease, 10th revision (ICD-10) code corresponding to T2DM was first identified, ^bData based on the year in which the ICD-10 code corresponding to ASCVD or HF was first identified among patients with T2DM.